BETAMETHASONE VALERATE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alembic	BETAMETHASONE VALERATE	betamethasone valerate	AEROSOL, FOAM;TOPICAL	215832	ANDA	Alembic Pharmaceuticals Limited	46708-708-31	1 CAN in 1 CARTON (46708-708-31) / 100 g in 1 CAN	2024-08-22
Alembic	BETAMETHASONE VALERATE	betamethasone valerate	AEROSOL, FOAM;TOPICAL	215832	ANDA	Alembic Pharmaceuticals Limited	46708-708-50	1 CAN in 1 CARTON (46708-708-50) / 50 g in 1 CAN	2024-08-22
Alembic	BETAMETHASONE VALERATE	betamethasone valerate	AEROSOL, FOAM;TOPICAL	215832	ANDA	Alembic Pharmaceuticals Inc.	62332-708-31	1 CAN in 1 CARTON (62332-708-31) / 100 g in 1 CAN	2024-08-22
Alembic	BETAMETHASONE VALERATE	betamethasone valerate	AEROSOL, FOAM;TOPICAL	215832	ANDA	Alembic Pharmaceuticals Inc.	62332-708-50	1 CAN in 1 CARTON (62332-708-50) / 50 g in 1 CAN	2024-08-22
Padagis Israel	BETAMETHASONE VALERATE	betamethasone valerate	AEROSOL, FOAM;TOPICAL	078337	ANDA	Padagis Israel Pharmaceuticals Ltd	45802-053-01	1 CAN in 1 CARTON (45802-053-01) / 50 g in 1 CAN	2013-01-15
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis identifies key suppliers for betamethasone valerate active pharmaceutical ingredient (API) and its associated drug products. It highlights market concentration, potential risks, and the operational landscape for pharmaceutical manufacturers relying on this corticosteroid.

What is Betamethasone Valerate?

Betamethasone valerate is a synthetic corticosteroid with potent anti-inflammatory, antipruritic, and vasoconstrictive properties. It is formulated into various topical preparations, including creams, ointments, lotions, and foams, for the treatment of dermatological conditions such as eczema, psoriasis, dermatitis, and allergic reactions. Its efficacy lies in its ability to suppress the immune response and reduce inflammation at the application site.

The molecule's chemical structure, 17,21-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-valerate, contributes to its lipophilicity, allowing for effective penetration into the skin. The global market for topical corticosteroids, a segment betamethasone valerate significantly contributes to, is projected to grow due to increasing prevalence of skin disorders and advancements in formulation technology.

Who are the Key Betamethasone Valerate API Suppliers?

The production of betamethasone valerate API is concentrated among a limited number of global manufacturers. This concentration poses potential supply chain vulnerabilities for drug product formulators. Key API suppliers include:

Diosynth Biotechnologies: A subsidiary of Merck KGaA, Diosynth is a significant player in steroid API manufacturing, including betamethasone derivatives. They operate multiple cGMP-compliant facilities globally.
CordenPharma: CordenPharma offers custom manufacturing services for APIs, including complex steroids. They have a dedicated facility in Caponago, Italy, focused on steroidal APIs.
Siegfried AG: Siegfried is a Swiss-based contract development and manufacturing organization (CDMO) that produces APIs for various therapeutic areas, with a presence in steroid synthesis.
Hengrui Medicine: A major Chinese pharmaceutical company, Hengrui is involved in the production of a wide range of APIs, including betamethasone valerate. Their production capacity is substantial.
Abbott Laboratories (now AbbVie): While historically a significant producer, specific API manufacturing operations for betamethasone valerate may have shifted or been divested. However, their legacy in steroid production remains relevant.
Zhejiang NHU Co., Ltd.: A prominent Chinese API manufacturer with diverse product portfolios, including corticosteroids.

These suppliers often operate under strict regulatory oversight from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance with Good Manufacturing Practices (GMP) is essential for API quality and market access.

What is the Landscape of Betamethasone Valerate Drug Product Manufacturers?

The manufacturing of finished drug products containing betamethasone valerate is more fragmented than API production, involving both originator brands and numerous generic manufacturers. This indicates a competitive market for topical corticosteroid formulations.

Major Branded Products and Their Manufacturers

Several well-established branded products utilize betamethasone valerate. These often benefit from established market share and brand recognition.

Diprosone® (Schering-Plough, now Merck & Co.): A widely recognized brand for betamethasone valerate creams and ointments.
Celestoderm® (Bayer): Another prominent brand with various topical formulations.
Betnovate® (GlaxoSmithKline): A long-standing brand in the topical corticosteroid market.

These originator companies typically have robust supply chains, often with multiple approved API suppliers and significant in-house or contracted drug product manufacturing capabilities.

Key Generic Manufacturers

The generic market for betamethasone valerate formulations is extensive, with numerous companies worldwide producing bioequivalent versions of branded products. These manufacturers are crucial for market access and affordability.

Teva Pharmaceutical Industries: A global leader in generic pharmaceuticals, Teva manufactures a broad range of topical products, including betamethasone valerate creams and ointments.
Mylan N.V. (now Viatris): Viatris, formed by the merger of Mylan and Upjohn, is a significant producer of generic dermatological products, including betamethasone valerate.
Sun Pharmaceutical Industries: An Indian multinational pharmaceutical company, Sun Pharma is a major player in the global generics market, with a strong presence in topical formulations.
Lupin Limited: Another Indian pharmaceutical company with a significant generics portfolio, including dermatologicals.
Accord Healthcare: A UK-based generic pharmaceutical company that markets and distributes betamethasone valerate products across Europe.
Egis Pharmaceuticals: A Hungarian pharmaceutical company with a range of generic prescription drugs.
Perrigo Company: Specializes in over-the-counter (OTC) and generic prescription products.

Generic manufacturers rely heavily on consistent access to high-quality betamethasone valerate API from suppliers. Their business models emphasize cost-efficiency and rapid market entry upon patent expiry.

What are the Regulatory Considerations for Betamethasone Valerate?

The regulatory environment significantly impacts the supply chain for betamethasone valerate. Compliance with stringent guidelines from health authorities is mandatory for both API and finished drug product manufacturers.

Good Manufacturing Practices (GMP): All manufacturing facilities producing betamethasone valerate API and drug products must adhere to cGMP standards. This includes rigorous quality control, process validation, and documentation. Regulatory agencies like the FDA conduct regular inspections to ensure compliance.
Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory authorities. These confidential documents detail the chemistry, manufacturing, and controls (CMC) of the API. Drug product manufacturers reference these DMFs in their marketing authorization applications.
Marketing Authorization Applications (MAAs) / New Drug Applications (NDAs) / Abbreviated New Drug Applications (ANDAs): Manufacturers of finished drug products must obtain approval from relevant health authorities before marketing their products. Generic manufacturers submit ANDAs, which rely on demonstrating bioequivalence to an approved reference listed drug.
Pharmacopoeial Standards: Betamethasone valerate must meet the specifications outlined in official pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These standards define purity, impurity limits, and other critical quality attributes.
Impurity Profiling: Regulatory authorities increasingly scrutinize impurity profiles of APIs. Identification and control of genotoxic and other harmful impurities are paramount. Manufacturers must have robust analytical methods to detect and quantify these.
Supply Chain Security: Ensuring the integrity and security of the supply chain against counterfeiting and diversion is a growing regulatory concern. Traceability requirements, such as serialization, are becoming more prevalent.

What are the Potential Supply Chain Risks?

The betamethasone valerate supply chain faces several risks that pharmaceutical companies must proactively manage.

API Supplier Concentration and Dependence

Limited Number of Suppliers: As identified, the API market is concentrated. A disruption at a major supplier (e.g., due to a manufacturing issue, regulatory action, or geopolitical event) can have widespread impacts on API availability for numerous drug product manufacturers.
Geographic Concentration: A significant portion of API manufacturing, particularly for steroids, is located in specific regions (e.g., China, India). This geographic concentration increases vulnerability to regional events like natural disasters, trade disputes, or public health crises.
Single-Sourcing Risks: Companies that rely on a single API supplier face significant risk if that supplier experiences production issues or ceases operations.

Quality and Regulatory Compliance Issues

GMP Violations: Any FDA warning letters, import alerts, or other regulatory actions against an API supplier can halt or severely restrict the supply of qualified API.
Impurity Excursions: Unexpected increases in impurity levels in an API batch can lead to batch rejections, product recalls, and regulatory scrutiny, impacting downstream drug product manufacturing schedules.
Raw Material Sourcing: The synthesis of betamethasone valerate requires specific starting materials and intermediates. Disruptions in the supply of these upstream components can cascade through the API manufacturing process.

Logistics and Geopolitical Factors

Transportation Disruptions: Global shipping delays, port congestion, and increased freight costs can impact the timely delivery of both API and finished products.
Trade Policies and Tariffs: Changes in international trade agreements or the imposition of tariffs can affect the cost and availability of raw materials and finished goods.
Geopolitical Instability: Conflicts or political instability in key manufacturing regions can disrupt production and logistics.

Patent Expiries and Generic Competition

Increased Demand for API: As originator product patents expire, demand for betamethasone valerate API from generic manufacturers typically surges. This can strain existing supplier capacity and lead to price increases or shortages if capacity is not scaled accordingly.
New Entrants: The generic market is highly competitive. New entrants can increase demand for API and potentially drive down pricing, impacting the profitability of established generic manufacturers.

Strategies for Supply Chain Resilience

Pharmaceutical companies can implement several strategies to mitigate these risks and build a more resilient supply chain for betamethasone valerate:

Dual/Multi-Sourcing: Qualify and maintain relationships with at least two independent API suppliers, preferably from different geographic regions. This diversification reduces reliance on a single source.
Supplier Audits and Relationship Management: Conduct rigorous and regular audits of all critical suppliers. Foster strong working relationships, encouraging transparency regarding their own supply chain risks and contingency plans.
Inventory Management: Maintain adequate safety stocks of critical raw materials and finished products, balancing the costs of holding inventory against the risks of stockouts.
Geographic Diversification of Manufacturing: For drug product manufacturers, consider diversifying manufacturing sites or contracting with CMOs in different geographic locations.
Contingency Planning: Develop detailed contingency plans for various disruption scenarios, including alternative suppliers, logistics routes, and emergency production protocols.
Regulatory Intelligence: Stay abreast of evolving regulatory requirements and ensure all suppliers and internal processes are compliant. Proactive engagement with regulatory authorities can help anticipate and address potential issues.
Long-Term Contracts: Establish long-term supply agreements with key API suppliers to ensure a stable supply and predictable pricing, while also allowing for flexibility.
Vertical Integration (Selective): In some cases, strategic backward integration into critical intermediate or API manufacturing may be considered for highly essential or narrowly sourced components, though this involves significant capital investment and expertise.

Key Takeaways

The betamethasone valerate market is characterized by a concentrated API supply base and a more fragmented generic drug product manufacturing landscape. Pharmaceutical companies must navigate regulatory complexities and manage significant supply chain risks, including supplier dependency, quality compliance, and geopolitical factors. Proactive strategies such as multi-sourcing, robust supplier management, and diligent contingency planning are essential for ensuring uninterrupted access to this critical dermatological therapy.

Frequently Asked Questions

1. How does the regulatory environment in China and India impact the global supply of betamethasone valerate API?

Regulatory actions, such as facility closures or import alerts, by the FDA or EMA against API manufacturers in China and India can significantly disrupt global supply chains, as these regions are major production hubs for betamethasone valerate. Manufacturers in these regions must consistently meet international GMP standards.

2. What are the primary differences in the supply chain for a branded betamethasone valerate product versus a generic one?

Branded products often have established, long-term relationships with specific API suppliers and may have higher safety stock levels. Generic manufacturers, driven by cost efficiency and market entry speed, typically qualify multiple API suppliers and may operate with leaner inventory to remain competitive.

3. How can a drug product manufacturer assess the quality and reliability of a new betamethasone valerate API supplier?

Assessment involves comprehensive on-site audits of manufacturing facilities to verify GMP compliance, review of Drug Master Files (DMFs), evaluation of the supplier's quality management system, verification of their regulatory history, and qualification of API batches through rigorous analytical testing.

4. What is the typical lead time for securing a new supply of betamethasone valerate API from a qualified supplier?

The lead time can vary significantly but typically ranges from 3 to 12 months. This includes the qualification process, initial batch production, analytical testing, and shipping. Long-term contracts and established relationships can sometimes shorten this timeframe for repeat orders.

5. Are there specific regional dependencies for the raw materials needed to synthesize betamethasone valerate?

The synthesis of complex steroids like betamethasone valerate involves numerous chemical intermediates. Some of these intermediates may have their own limited supplier bases or regional concentrations, creating upstream dependencies that can affect the overall supply chain for the final API.

Citations

[1] Diosynth Biotechnologies. (n.d.). Steroid Hormones & API Manufacturing. Retrieved from https://www.diosynthbio.com/services/steroid-hormones/

[2] CordenPharma. (n.d.). Steroid APIs. Retrieved from https://cordenpharma.com/services/contract-manufacturing/active-pharmaceutical-ingredients/steroid-apis/

[3] Siegfried AG. (n.d.). APIs. Retrieved from https://www.siegfried.ch/products-services/apis/

[4] Hengrui Medicine. (n.d.). APIs. (Company reports and investor information typically detail product portfolios; specific API pages may not always be publicly available).

[5] Viatris Inc. (n.d.). Our Products. (General product information and therapeutic areas are listed; specific betamethasone valerate product details are available through product search). Retrieved from https://www.viatris.com/en/products

[6] Sun Pharmaceutical Industries Ltd. (n.d.). Products. (Company website lists therapeutic areas and product types). Retrieved from https://www.sunpharma.com/products/

[7] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP) Information. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/good-manufacturing-practice-gmp-information

[8] European Medicines Agency. (n.d.). Manufacturing and Quality. Retrieved from https://www.ema.europa.eu/en/human-regulatory/manufacturing-quality

Suppliers and packagers for generic pharmaceutical drug: BETAMETHASONE VALERATE